Shifting the focus in lymphoma treatment
Novel agents for myeloma related bone disease
Exciting advances in checkpint inhibitors CAR T-cells, and ALK inhibitors
Steven T. Rosen
What is in the future for T-cell lymphoma?
The power of venetoclax